Susanne Kindermann

Title: Innovator Spotlight: Susanne Kindermann

Introduction

Susanne Kindermann, an accomplished inventor based in Liestal, Switzerland, has made significant contributions to the field of biotechnology. With a total of seven patents to her name, her work primarily focuses on advancing growth hormone therapies, which have lasting implications for various medical conditions.

Latest Patents

Among her latest innovations are two notable patents. The first patent introduces PEGylated recombinant human growth hormone compounds. This invention involves a chemically modified human growth hormone (rhGH) that utilizes a transient linker comprised of polyethylene glycol. The modification enhances the longevity of rhGH activity compared to its unmodified counterpart, leading to reduced dosing requirements and diminished occurrences of lipoatrophy. Additionally, this modified rhGH can be used for the treatment and prevention of diseases where growth hormone application offers therapeutic benefits.

The second patent pertains to dry growth hormone composition transiently linked to a polymer carrier. This innovation is significant, as it pertains to stable dry compositions of rhGH containing lyoprotectants and other excipients. These compositions are designed to remain stable for at least one year at temperatures between 2-8°C. The invention also encompasses methods for manufacturing the compositions, suitable containers for storage, as well as comprehensive kits for practical use.

Career Highlights

Susanne's career has flourished in the realms of pharmaceutical development. She has notably worked with Ascendis Pharma’s Endocrinology Division and the Growth Disorders Division, where her research has directly impacted the advancement of therapeutic approaches in endocrinology. Her role in these divisions showcases her expertise and commitment to developing pioneering solutions in health care.

Collaborations

Throughout her career, Susanne has collaborated with distinguished colleagues, including Harald Rau and Thomas Wegge. These professional partnerships have been pivotal in driving her research endeavors and in expanding the frontiers of growth hormone applications.

Conclusion

Susanne Kindermann's dedication to the field of biotechnology and her innovative patents underline her importance as a leading inventor in the pharmaceutical industry. With continued advancements in her research, her contributions will likely play a pivotal role in improving treatment methods for various growth hormone-related conditions, showcasing the transformative potential of her work.